Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies

European Journal of Neurology

Volumn 21, Issue 4, 2014, Pages 623-629

  Kroigard T ^a   Schroder H D ^a   Qvortrup, C ^a   Eckhoff, L ^a   Pfeiffer, P ^a   Gaist, D ^a   Sindrup, S H ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CIPN; Docetaxel; Nerve conduction studies; Oxaliplatin; Quantitative sensory testing; Skin biopsy

Indexed keywords

DOCETAXEL; OXALIPLATIN;

ADULT; AGED; ARTICLE; BRAIN DAMAGE; BREAST CANCER; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DRUG INDUCED DISEASE; DRUG TOXICITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NERVE FUNCTION; NEUROLOGIC DISEASE; NEUROLOGICAL SYMPTOM SCORE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUANTITATIVE SENSORY TESTING; SCORING SYSTEM; SENSORY EVALUATION; SKIN BIOPSY;

CIPN; DOCETAXEL; NERVE CONDUCTION STUDIES; OXALIPLATIN; QUANTITATIVE SENSORY TESTING; SKIN BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOPSY; HUMANS; MIDDLE AGED; NEOPLASMS; NEURAL CONDUCTION; ORGANOPLATINUM COMPOUNDS; POLYNEUROPATHIES; SENSATION; SKIN; TAXOIDS;

EID: 84897919516     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12353     Document Type: Article

References (22)

1. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007; 25: 2205-2211.
2. Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has a good long-term prognosis: a 1- to 13-year evaluation. J Neurol 2012; 259: 1936-1943.
3. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29: 21-33.
4. Leonard GD, Wright MA, Quinn MG, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005; 5: 116.
5. Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain 2009; 144: 245-252.
6. Speck RM, Sammel MD, Farrar JT, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 2013; 9: e234-e240.
7. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005; 32: 51-60.
8. England JD, Gronseth GS, Franklin G, et al. Distal symmetrical polyneuropathy: a definition for clinical research. A report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Arch Phys Med Rehabil 2005; 86: 167-174.
9. Smith AG, Howard JR, Kroll R, et al. The reliability of skin biopsy with measurement of intraepidermal nerve fiber density. J Neurol Sci 2005; 228: 65-69.
10. Chien HF, Tseng TJ, Lin WM, et al. Quantitative pathology of cutaneous nerve terminal degeneration in the human skin. Acta Neuropathol 2001; 102: 455-461.
11. Burkgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 2011; 77: 980-986.
12. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011; 16: CD005228.
13. Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-596.
14. Dyck PJ, Boes CJ, Mulder D, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst 2005; 10: 158-173.
15. Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA, Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002; 72: 596-601.
16. Merkies IS, Schmitz PI, van der Meché FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Neurology 2000; 54: 943-949.
17. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 2005; 123: 231-243.
18. Joint Task force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2010; 15: 79-92.
19. Lauria G, Bakkers M, Schmitz C, et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst 2010; 15: 202-207.
20. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute - Common Toxicity Scale. J Peripher Nerv Syst 2007; 12: 210-215.
21. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013; 31: 2699-2707.
22. Pourhamidi K, Dahlin LB, Englund E, Rolandsson O. Evaluation of clinical tools and their diagnostic use in distal symmetric polyneuropathy. Prim Care Diabetes 2013; doi: 10.1016/j.pcd.2013.04.004 [Epub ahead of print].